EP3246021

BRISTOL-MYERS SQUIBB HOLDINGS IRELAND
Application Number
EP17175864A
Filing Date
Feb 24, 2011
Status
Revoked
Mar 22, 2024
Grant Date
Nov 13, 2019
External Links
Slate, Register

Biblio Summary

The patent EP3246021B1 was granted on Nov 13, 2019 by Bristol-Myers Squibb Holdings Ireland The patent is currently Revoked.

The table below shows 12 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

STADAAug 13, 2020ADMISSIBLE
INTAS PHARMACEUTICALS LTD.Aug 12, 2020WITHDRAWN
GENERICS UKAug 10, 2020ADMISSIBLE
ALFRED E. TIEFENBACHER (GMBH & CO. KG)Aug 7, 2020ADMISSIBLE
WITTKOPP, ALEXANDERAug 7, 2020ADMISSIBLE
KUTZENBERGER WOLFF & PARTNERAug 6, 2020ADMISSIBLE
VON SEEBACH, MALTEAug 6, 2020ADMISSIBLE
ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.Aug 6, 2020ADMISSIBLE
TEVAAug 4, 2020ADMISSIBLE
ZENTIVA K.S.Aug 4, 2020ADMISSIBLE
SANDOZAug 3, 2020ADMISSIBLE
KRKA, D.D., NOVO MESTOAug 3, 2020WITHDRAWN

The table below shows the patents of Bristol-Myers Squibb Holdings Ireland that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP3251660Apixaban FormulationsOct 16, 201920
EP3257500Apixaban FormulationsOct 16, 201920
EP3017811Apixaban FormulationsDec 5, 201818

Dossier Documents of the Patent

The documents dossier of the patent at EPO including all essential records in the patent's lifecycle, from filing to grant to oppositions.